Key result
Adiponectin negatively correlates with BMI but positively tracks HbA1c in diabetic CAD patients.
Why the study?
Reduced adiponectin levels have been associated with obesity, type II diabetes mellitus, and coronary artery disease, but their relationship with BMI and HbA1c in CAD patients with and without diabetes needed evaluation.
Does serum adiponectin correlate with BMI and HbA1c in coronary artery disease patients with and without type II diabetes mellitus?
Observational (n=90)
No
Does serum adiponectin correlate with BMI and HbA1c in coronary artery disease patients with and without type II diabetes mellitus?
Effect estimate: r=-0.14
Serum adiponectin levels are significantly altered in CAD patients with type II diabetes and inversely correlate with BMI, suggesting its potential utility as a biomarker for metabolic and cardiovascular risk assessment.
Supports adiponectin investigation as biomarker in diabetic CAD; leaves open prognostic value and practice implications.
Background:Adiponectinis an adipocyte-derived hormone with anti-inflammatory, anti-atherogenic, and insulin-sensitizing properties. Reduced adiponectin levels have been associated with obesity, type II diabetes mellitus, and coronary artery disease (CAD). The present study aimed to evaluate the relationship between adiponectin, body mass index (BMI), and glycosylated hemoglobin (HbA1c) in CAD patients with and without type II diabetes mellitus.Methodology:This comparative observational study was conducted in the Department ofGeneral Medicine at Sree Mookambika Institute of Medical Sciences from January 2025 to December 2026. A total of 90 subjects were included, among whom 30 patients had CAD with type II diabetes mellitus. Blood samples were collected under aseptic precautions for estimation of serum adiponectin and HbA1c levels. BMI was calculated using standard WHO criteria. Statistical analysis was performed to determine correlations and group differences.Results:The mean BMI was significantly higher among diabetic subjects compared to CAD patients with diabetes (p=0.001). HbA1c levels were also significantly elevated in diabetic patients (p=0.001). Adiponectin showed a negative correlation with BMI (r=-0.14) and a positive correlation with HbA1c (r=0.56) among CAD patients with diabetes mellitus.Conclusion:Altered adiponectin levels are significantly associated with obesity and glycemic status in CAD patients with type II diabetes mellitus. Adiponectin may serve as a potential biomarker for metabolic and cardiovascular risk assessment.
No takes yet. Share an insight, caveat, or question.
Chettiyar et al. (2026) conducted an observational in Coronary artery disease with and without type 2 diabetes mellitus (n=90). Type 2 Diabetes Mellitus vs. Coronary artery disease without type 2 diabetes mellitus was evaluated on Correlation between plasma adiponectin and BMI in CAD patients with diabetes mellitus (r=-0.14). Serum adiponectin levels demonstrated a negative correlation with body mass index (r=-0.14) and a positive correlation with HbA1c (r=0.56) among coronary artery disease patients with diabetes mellitus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: